Ultragenyx Pharma (RARE) Has Multiple Catalysts in 2015 - Jefferies

March 26, 2015 8:36 AM

Jefferies analyst Ryan Martins reiterated a Buy rating and $74 price target on Ultragenyx Pharma (NASDAQ: RARE) noting multiple catalysts ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found